Amphastar Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.: Annual Revenue Growth Compared

Biotech Revenue Battle: Amphastar vs. Viridian from 2014-2023

__timestampAmphastar Pharmaceuticals, Inc.Viridian Therapeutics, Inc.
Wednesday, January 1, 20142104610004320000
Thursday, January 1, 20152515190002538000
Friday, January 1, 20162551650003337000
Sunday, January 1, 20172401750004003000
Monday, January 1, 20182946660008386000
Tuesday, January 1, 20193223570004461000
Wednesday, January 1, 20203498460001050000
Friday, January 1, 20214377680002963000
Saturday, January 1, 20224989870001772000
Sunday, January 1, 2023644395000314000
Loading chart...

In pursuit of knowledge

A Tale of Two Biotechs: Revenue Growth from 2014 to 2023

In the dynamic world of biotechnology, Amphastar Pharmaceuticals, Inc. and Viridian Therapeutics, Inc. present a fascinating study in contrasts. Over the past decade, Amphastar has demonstrated a robust revenue growth trajectory, with a remarkable increase of over 200% from 2014 to 2023. Starting at approximately $210 million in 2014, Amphastar's revenue surged to nearly $645 million by 2023, reflecting its strategic market positioning and successful product lines.

Conversely, Viridian Therapeutics, Inc. has faced a more challenging path. Despite a promising start with revenues peaking at around $8.4 million in 2018, the company saw a significant decline, with revenues dropping to just $314,000 in 2023. This stark contrast highlights the volatile nature of the biotech industry, where innovation and market adaptation are key to survival and growth.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025